UNSPSC 51381704: Acetaminophen mercapturate

This classification denotes an analgesic and antipyretic with the molecular formula C13H16N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R86SEU3G6U, chemically known as l-cysteine, n-acetyl-s-(5-(acetylamino)-2-hydroxyphenyl)-, but more generally known as acetaminophen mercapturate, which bears US NIH Compound Identifier 83967. European Medicines Agency schedules acetaminophen mercapturate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG.

Most nations, for tariff purposes, schedule acetaminophen mercapturate under HS 29242990. SMILES: CC(=O)NC1CCC(C(C1)SC[C@@H](C(=O)O)NC(=O)C)O.

UNSPSC 51381704 Acetaminophen mercapturate is a Commodity code that in practice captures state and local procurement of pharmaceuticals and related health products rather than the narrow chemical compound its name suggests. Recent opportunities under this code reflect purchases of naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment programs—acquisitions driven by public health agencies, state health departments, and cooperative purchasing alliances serving multiple jurisdictions. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing organizations; Seminole County, Florida and the Texas Health and Human Services Commission appear as recent active buyers, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates procurement across multiple states including Oregon.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with bids due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program—an exploratory solicitation designed to inform future procurement strategy rather than award immediate contracts. MMCAP posted RFP S1070000015802 on January 20, 2026, seeking multiple manufacturers for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The code shows modest but active pursuit by state and regional health procurement bodies focused on cost control, supply chain efficiency, and community health initiatives.